On August 25, 2022 Shanghai Alpha Biopharma reported the last patient visit has taken place in its Phase II/III trial of zorifertinib in patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) and CNS metastases (Press release, ChinaBio, AUG 25, 2022, View Source [SID1234618713]). The trial enrolled 492 patients at 55 study sites. In previous clinical and preclinical tests, zorifertinib showed high blood-brain barrier (BBB) penetration, anti-tumor activity in metastatic CNS lesions, overall efficacy in both CNS and extra-cranial diseases, and a safety profile similar to other EGFR-TKI drugs. AlphaBio acquired zorifertinib from AstraZeneca.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!